重组复合干扰素治疗慢性丙型肝炎的临床研究（Clinical study of recombinant interferon in chronic hepatitis C）.docVIP

下载本文档

4
0
约5.2千字
约 5页
2018-05-30 发布于河南
举报
版权申诉

重组复合干扰素治疗慢性丙型肝炎的临床研究（Clinical study of recombinant interferon in chronic hepatitis C）.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

重组复合干扰素治疗慢性丙型肝炎的临床研究（Clinical study of recombinant interferon in chronic hepatitis C）

重组复合干扰素治疗慢性丙型肝炎的临床研究（Clinical study of recombinant interferon in chronic hepatitis C） Clinical study of recombinant interferon in chronic hepatitis C 2011-02-27 Yao Guangbi, Fu Xixian, Xu Daozhen, Hao Lianjie, Huangfu Yushan, Su Chunxin, Tian Gengshan [Abstract] Objective To compare the efficacy and safety of two doses of recombinant interferon Interferon (Consensus) and recombinant interferon alpha -2a (IFN alpha -2a) in the treatment of chronic hepatitis C (CIFN). Methods 187 patients with newly diagnosed chronic hepatitis C (Bing Gan) were randomly divided into three groups, respectively: CIFN 15 g (A group) 61 cases, 9 g (B group) 65 cases and IFN alpha -2a 3 MU (C group) 61 cases, 3 times in 1 weeks, 24 weeks. Follow up at 24 weeks after completing treatment. The end of the test to treatment and follow-up of alanine aminotransferase (ALT) normalization and hepatitis C virus RNA (HCV RNA) by reverse transcriptase polymerase chain reaction (RT-PCR) to check the negative assessment of drug effects of short-term and long-term, and observed adverse reactions. Results 180 patients were treated for 24 weeks, CIFN, 15 g, 56 cases, 9 g group, 63 cases and IFN -2a group 61 cases. After 24 weeks of treatment, ALT, B and C were 76.9%, 68.3% and 57.4% respectively, and the negative conversion rates of HCV and RNA were 89.6%, 73.6% and 60.4%, respectively. There were significant differences between group A and group C (P0.05 and P0.01), respectively (and A). At 48 weeks, ALT, B and C were 78.8%, 63.9% and 55% respectively, and the negative conversion rates of HCV and RNA were 75%, 65.4% and 54.7%, respectively. There were significant differences between group A and group C (P0.01 and P0.05), respectively (and A). The immediate effective rates of the three groups were 70.8%, 54.7% and 34%, respectively. The long-term effective rates were 64.6%, 51.9% and 43.4% respectively. The short-term and long-term effects of A group were significantly higher than those in group C (P0.01